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Summary The relationships between resistance to adriamycin, vincristine, colchicine and etopside, expression
of P-glycoprotein and CP22 (sorcin), and resistance modification by verapamil and cyclosporin A have been
studied in a panel of multidrug-resistant (MDR) mouse tumour cell lines. Whereas there was a generally good
correlation between the degree of resistance and the amount of P-glycoprotein, no relationship between
resistance and CP22 expression was seen. At 3.3 luM verapamil, the sensitisation of the MDR cell lines was no
greater than that of the parent line. At 6.6 lAM verapamil, however, sensitisation of the MDR lines generally
exceeded that of the parent line, although the line CR 2.0, expressing very high levels of P-glycoprotein was an
exception. Little sensitisation to etoposide was seen in any of the lines. When cyclosporin A was used as the
sensitiser at either 2.1 or 4.2 1uM, there was a greater effect in lines expressing moderate to high levels of
P-glycoprotein than in the parent line, although this tendency was less for adriamycin than for the other
cytotoxics. Sensitisation to etoposide was much greater with cyclosporin A than with verapamil. At low levels
(<1 1 M) of CsA, however, sensitisation to colchicine was greater in the parent line than in cell line CR 2.0.
These studies indicate that chemosensitisation by verapamil and cyclosporin A is extremely complex, depend-
ing upon sensitiser dose, the particular cytotoxic and the cell line. At low doses of the sensitisers, the
sensitisation may be greater in lines expressing low levels of P-glycoprotein than in lines showing high levels.
The biochemical basis of the multidrug-resistant (MDR)
phenotype and the development of strategies to overcome
MDR have been the subjects of intensive research over the
past several years. Studies using cell lines resistant to multiple
drugs have shown that, in general, MDR is associated with
hyperexpression of P-glycoprotein and reduced intracellular
drug accumulation (Riordan & Ling, 1985; Bradley et al.,
1988). In addition some resistant cell lines show changes in
expression of a low molecular weight, cytosolic, calcium-
binding protein known as V19 (Meyers & Biedler, 1981),
CP22 (Koch et al., 1986b) or sorcin (van der Bliek et al.,
1986). In many cases MDR is partially reversible by a variety
of agents, including verapamil (VRP) (Tsuruo et al., 1982a,b;
Twentyman et al., 1986), calmodulin inhibitors (Tsuruo et
al., 1982a,b) and cyclosporins (Slater et al., 1986a,b; Twenty-
man et al., 1987; Twentyman, 1988; Coley et al., 1989a).
Although this phenotypic reversal is not understood well in
molecular terms, recent data indicate that both VRP and
cyclosporin A (CsA) may modify drug sensitivity by binding
to P-glycoprotein (Cornwell et al., 1987; Safa et al., 1987;
Naito & Tsuruo, 1989), thus reducing the efficacy of drug
efflux (Dano, 1973; Inaba et al., 1979; Bradley et al., 1988).
In addition, little or no reversal of MDR is seen in atypical
MDR variants which fail to express P-glycoprotein (Beck et
al., 1987; Cole et al., 1989) and transfected NIH 3T3 AM
colonies expressing a complementary DNA, ADRII, which is
thought to encode P-glycoprotein, exhibit the classic MDR
phenotype and reversal of drug resistance when exposed to
VRP (Croop et al., 1987). These observations suggest that
the gene product encoded by ADRII alone enables the trans-
fected MDR colonies to respond to VRP in a manner similar
to other MDR cell lines. Indeed both CsA and VRP have
been shown to reverse the drug accumulation defect seen in
MDR cells (Nooter et al., 1989; Coley et al., 1989b). Recent
studies have demonstrated that the binding of VRP to the
plasma membranes of MDR cells is inhibited by other cal-
cium antagonists and also by adriamycin (ADM), vincristine
(VCR) and colchicine (COL), suggesting that VRP, ADM,
VCR and COL bind to P-glycoprotein competitively and are
transported out of the cell by the same mechanism (Naito &
Tsuruo, 1989). Furthermore, we have recently shown that
MDR variants of the EMT6/Ca/VJAC mouse tumour cell
line are cross-resistant to VRP and that resistance to VRP
correlates with the degree of resistance to the inducing agent
and with the amount-of membrane P-glycoprotein (Reeve et
-al., 1989). These observations are consistent with the conten-
tion that VRP is indeed a substrate for the P-glycoprotein
pump.
If VRP and CsA potentiate the actions of cytotoxic agents
via interaction with P-glycoprotein then given the aforemen-
tioned findings it seems likely that the degree of sensitisation
may be quantitatively related to the sensitiser dose, the
amount of P-glycoprotein and the affinities of both the sen-
sitiser and the cytotoxic drug for P-glycoprotein. The present
study examines the relationship between these parameters in
a panel of mouse tumour cell lines in which MDR has been
induced by different cytotoxic drugs and which exhibit
different levels of P-glycoprotein and CP22 expression.
Materials and methods
Cells and medium
The EMT6/Ca/VJAC mouse mammary carcinosarcoma cell
line (Rockwell et al., 1972; Twentyman, 1980) grows as an
attached monolayer on plastic and has a doubling time of
approximately 12 h during exponential growth. The parent
cell line is referred to as EMT6/P in this paper. Cells were
grown in Eagle's MEM with Earle's salts supplemented with
penicillin and streptomycin (all Gibco Biocult) and with 20%
new born calf serum (Seralab Ltd). Chinese hamster MDR
cell line CHRC5, kindly supplied by Dr V. Ling and used as a
P-glycoprotein positive control, was grown in a MEM with
10% fetal calf serum (Gibco Biocult).
Cytotoxic drugs
The cytotoxic drugs used for induction of drug resistance
were adriamycin (ADM, Farmitalia), colchicine (COL,
Sigma) and vincristine (VCR, David Bull Labs). In addition,
etoposide (VP16, Bristol-Myers) was used in sensitivity test-
ing. VRP (Abbott Labs) and CsA (Sandoz Ltd) were used as
resistance-modifying agents.
Cytotoxic drugs were dissolved in sterile distilled water to
a concentration of 500Ig mlh'. Aliquots were stored at
- 70°C and diluted in sterile water immediately before use.
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For induction of resistance, drugs were added in a volume of
50-150 j4 to 5 ml of growth medium. VRP was diluted in
phosphate buffered saline. CsA was initially dissolved in
absolute ethanol and then diluted in medium so that the final
ethanol concentration did not exceed 0.2%.
Antibodies to P-glycoprotein and CP22
A mouse monoclonal antibody C219 (Kartner et al., 1985)
was generously supplied by Dr V. Ling.
An affinity purified monospecific rabbit antibody to the
cytosolic calcium binding protein CP22 (sorcin) was used to
detect CP22 in MDR EMT6 cells. The antibody was
prepared by lysis of CHRC5 cells in 10 mM Tris-HCl, pH 7.5,
followed by centrifugation to remove cell debris. The super-
natant was then subjected to gel filtration on Sephadex G75
(fine) and the fractions containing CP22 (>80% pure) were
collected. Rabbits were immunised with 0.5 mg of the
purified CP22 by subcutaneous injection with Freund's com-
plete adjuvant. Antibodies to CP22 were affinity purified with
nitrocellulose strips containing pure CP22 (after SDS gel
electrophoresis and electroblotting) (Koch et al., 1986a).
Induction ofresistance
Flasks of EMT6/P cells (25 cm2 flasks, I05 cells per flask)
were set up at a range of concentrations of the inducing
drug. From such an inoculum, flasks containing control cells
reach confluence in 3-4 days. Drug treated cells were
examined regularly and flasks were chosen which after a
period of 14 days contained viable cells which were
still sub-confluent. These were in 0.2lgml' ADM,
0.075 gg ml-' VCR and 0.05Agml-' COL. The selected
flasks were trypsinised and the cells subcultured into two new
flasks containing the inducing drug at the original dose and
twice the original dose. The latter was maintained until the
cells approached confluence, at which point the subculture
and doubling of drug dose was repeated. The whole process
continued through a number of cycles until the cells were
able to grow progressively at a drug concentration many
times the original concentration. Frozen stocks were estab-
lished of sublines growing in 1.0fgml-' ADM (AR 1.0),
1.0 g ml-' VCR (VR 1.0) and 0.2 and 2.0 gml iCOL
(CR 0.2 and CR 2.0). Each of these sublines has a doubling
time in the range 12-15 hours during exponential growth.
Determination ofresistance
To quantify the extent of drug resistance for the various
sublines, we used the MTT colorimetric assay (Mosmann,
1983; Carmichael et al., 1987; Twentyman & Luscombe,
1987). The optimisation of this assay as used in our
laboratory with the EMT6 cell line has previously been de-
scribed (Twentyman & Luscombe, 1987).
Cells were cultured in the absence of the inducing drug for
2-3 days before their drug sensitivity was determined. To set
up the assay, cells were trypsinised from monolayer and
diluted to 5 x 103 or 104cells ml-'. Aliquots of 0.2 ml were
pipetted into wells of 96-well tissue culture plates (Falcon
Plastics) and the plates were incubated for 2 hours. Drugs
were then added to the wells in a volume of 20gsl per well at
a range of concentrations, each dose being used in at least
three replicate wells. The dishes were then returned to the
incubator for a period of 3 days during which control cells
increased in number by 10-20 x. At the end of this time,
20ftl of a 5 mg ml-' solution of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Sigma) in PBS was
added to each well and the plate then incubated for a further
5 hours. The medium was then aspirated from each well and
200IlI DMSO added. The plate was shaken on an automatic
plate shaker for 10 min and the optical density of each well
was read on a Titertek Multiskan MCC ELISA reader at
540 nm and at a reference wavelength of 690 nm. From
graphs of the data it was possible to determine the dose of
drug to reduce the final optical density (and hence cell
number) to 50% of the control value.
In experiments using resistance modifiers (RMs), VRP and
CsA were added in a volume of 10jil per well 2 hours after
setting up the plates and the cytotoxics were added after a
further hour. Doses of the RMs were 2.1 and 4.2gLM (= 2.5
and 5.0;,gml-') (CsA) and 3.3 and 6.6LM (= 1.65 and
3.3;Lg ml-') (VRP), except where dose-response was being
specifically studied. Appropriate solvent controls were used
in all experiments.
Drug accumulation
The ability of the cell lines to accumulate a drug, resistance
to which is generally seen in MDR cells, was measured using
tritium-labelled daunomycin (DNR), an analogue of ADM.
The labelled compound (3H-DNR) (1.4 Ci mmol-'; New
England Nuclear) was stored at - 70°C in methanol. Cells
were inoculated into 3 cm diameter wells on 6-well multi-
plates (Sterilin Ltd) 48 hours before experiments were carried
out. Inititial numbers of cell per well were adjusted so that
the numbers 48 hours later would be equal for all cell types
and ranged from 4 x 104 per well to 1.2 x 105 per well. Cells
from resistant lines were grown in the absence of drug over
this period. To commence experiments, the medium was
aspirated from each well and replaced with 2 ml of medium
at 37°C containing the labelled compound (0.1 Ci ml-')
together with carrier DNR to a final concentration of 1 tlM.
After the appropriate incubation time, the medium was again
aspirated from each well and the cell monolayer rinsed three
times with ice cold PBS. One ml of distilled water was then
added to each well and the wells left for 2 hours for cell lysis
to occur. The contents ofeach well were then pipetted several
times and 0.5 ml transferred to a liquid scintillation vial
containing 10 ml of Aquasol (Dupont). The vials were
counted the following day on a Nuclear Chicago Isocap
liquid scintillation counter. A cell count was carried out on
three replicate wells of each cell type and this allowed the
determined values of isotope uptake per well to be corrected
to uptake per cell.
Preparation ofplasma membranes
The isolation of plasma membranes was accomplished as
previously described (Riordan & Ling, 1979). Briefly, cells
were disrupted using a Stansted cell disruptor. Following
differential centrifugation the microsomal pellets were applied
to a discontinuous sucrose gradient consisting of 60% (w/v),
45%, 31% and 16% sucrose, and centrifuged at 77,000g for
18 hours. Material banding at the three interfaces was col-
lected and solubilised in 0.1% sodium dodecyl sulphate
(SDS). Protein determinations were carried out using a BCA
protein assay kit (Pierce (UK) Ltd, Cambridge, England).
Preparation ofcytosolic extracts
Cells were suspended in 10 mM Tris-HCl (pH 7.5) on ice for
30 min and lysed by syringing through an 18 gauge needle.
Cell debris was removed by centrifugation (100,000g,
30 min) and the supernatant used as cytoplasmic extract.
Immunoblotting
For the immunodetection of P-glycoprotein, microsomal
membrane proteins were subjected to SDS-gel electrophoresis
according to Debenham et al. (1982). For the immunodetec-
tion of CP22, cytosolic proteins were separated on a discon-
tinuous gel system according to Laemmli (1970). Transfer of
resolved proteins from gels to nitrocellulose filter paper was
as described by Towbin et al. (1979). Protein transfer was
performed for 4 hours at 4°C at a constant current of 0.5 A
using a solution containing 0.0125 M Tris, 0.2 M glycine
(pH 8.5) and 20% methanol as the electrode buffer. After
transfer, additional protein binding sites on nitrocellulose
were blocked by incubation of the paper overnight in 5 mM
EDTA, 0.25% gelatin, 0.01 M NaN3, 0.15 M NaCl, 0.05 MCHEMOSENSITISATION BY VERAPAMIL AND CYCLOSPORIN A 91
Tris-base, and 0.05% Nonidet P40 (NGA buffer). The paper
was then incubated overnight at 4°C with the appropriate
antibody diluted in NGA buffer. '25l-labelled rabbit anti-
mouse IgGI was used to detect mouse monoclonal antibody
to P-glycoprotein. For rabbit antisera, '25I-protein A
autoradiography was used to visualise antibody binding to
protein bands.
Drug accumulation
Cellular accumulation of 3H-DNR by EMT6/P and the resis-
tant sublines is shown in Figure 2. It may be seen that all of
the resistant sublines show a considerably reduced ability to
accumulate the labelled drug.
Results
Resistance characteristics ofthe MDR sublines
A typical set of data from an experiment to determine the
ADM sensitivity of parent EMT6 cells and a number of the
resistant sublines is shown in Figure 1. Each point represents
the mean value of three separate wells and the lines are fitted
to the points by eye. In this example, the ID50 (dose to reduce
optical density to 50% of control) is 0.06jigml-' for parent
cells and 1.2,gml-' for subline CR0.2. The ratio of these
values is defined as the resistance factor,
RF = ID50 (resistant subline)
ID50 (parent line)
and is therefore 20.0 for subline CR0.2.
The results from a large number of experiments with the
various resistant lines are shown in Table I.
It may be seen that there are only minor differences
between sublines AR 1.0, VR 1.0 and CR 0.2 in the spectrum
of resistance. For each of them, the RF to ADM, VCR,
COL and VP16 are within a factor of 2 and there is no
consistent tendency for the RF to the inducing agent to be
higher than that to the other agents in the group. For subline
CR 2.0, resistance to ADM and COL is several times higher
than that to VCR or VP16.
P-glycoprotein expression
Figure 3 shows the detection of P-glycoprotein in the plasma
membranes of EMT6 MDR variants following Western blot-
ting and reaction with monoclonal antibody C219 to P-
glycoprotein. It can be seen that all of the MDR sublines
hyperexpress P-glycoprotein compared to the parent line.
Longer exposure of the autoradiograph revealed that the
parent line expresses low but detectable amounts of P-
glycoprotein. The ranking of the cell lines according to P-
glycoprotein expression was confirmed in two further
experiments and also on the basis of mRNA expression in
Northern blot analysis (data not shown). These data are
summarised in Table II.
CP22 expression
Figure 4 shows the detection of CP22 in cytosol extracts
from EMT6 MDR variants following Western blotting and
reaction with an affinity purified rabbit antiserum to CP22.
All cell lines were found to express CP22 protein with
marked hyperexpression occurring in AR 1.0, CR0.2 and
CR 2.0. The data are summarised in Table II.
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Figure 1 Response of EMT6 cell lines to adriamycin measured
using the MTT assay. * EMT/P; 0 AR 1.0; V VR 1.0;
A CR 0.2. The ID50 is the adriamycin dose to reduce the final
optical density to 50% of control.
Table I Resistance factors for variant lines
Cell line Resistance factora to
EMT6/ ADM VCR COL VP16
AR 1.0 69 (13) 43 (8) 50 (9) 64
43
n =8 n =5 n =5 n =2
VR 1.0 35 (8) 56 (13) 64 (8) 35
55
n=9 n=5 n=5 n=2
CR0.2 17 (3.1) 12 (2.6) 16 (3.6) 19 (3.7)
n=9 n=5 n=5 n=4
CR 2.0 183 43 181 (40) 69
197 48 74
n =2 n =2 n =4 n =2
aResistance factor= ID50 (resistant line)
ID50 (parent line)
Values are mean resistance factors from n separate experiments.
Values in parentheses are standard errors. When n = 2, the
individual values are given.
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Figure 2 Cellular accumulation of tritium-labelled daunomycin
with time. 0 EMT6/P; 0 AR 1.0; V VR 1.0; A CR 0.2;
A CR 2.0.
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Figure 3 Detection of P-glycoprotein in the plasma membranes
of EMT6 drug resistant variants and parent line following
Western blotting and reaction with monoclonal antibody C219.
The CHRC' cell line was used as positive control.
* I ~~~~~~~~~~~~~~~~~~~~~~~~i
192 P.R. TWENTYMAN et al.
Table II Protein expression in EMT6 cell lines
Expression of
Cell line P-glycoprotein Sorcin
EMT6/P + +
AR1.0 ++++ +++
VR1.0 +++ ++
CR 0.2 + + + + + +
CR 2.0 + + + + + + + + + +
The number of pluses indicates the intensity of the bands on
autoradiographs where + = weak signal, + + + + + = very intense
signal (see Figures 3 and 4).
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Figure 4 Detection of CP22 in cytosol extracts from EMT6 drug
resistant variants and parent line following Western blotting and
reaction with an affinity purified rabbit antiserum to CP22.
Chemosensitisation by verapamil
Table III shows the sensitisation ratios,
SR = ID50 in absence of modifier
ID50 in presence of modifier
achieved when the parent and its MDR sublines are exposed
to ADM, VCR, COL or VP16 in the presence of 3.3 liM and
6.6 fLMVRP. No effects on cell growth were produced by
VRP alone at these dose levels. It can be seen that the parent
line is sensitised to all four drugs in the presence of 3.3 jAM
VRP and that a modest increase in SR is obtained by
increasing the VRP dose to 6.6 gM. Although sensitisation of
lines AR 1.0, VR 1.0 and CR 0.2 to ADM, COL and, to a
lesser extent, VP 16 is obtained in the presence of 3.3 l.M
VRP it can be seen that, at this dose, the SRs for most MDR
lines are generally less than, or no different from, those of the
parent line. SRs greater than those observed for the parent
line are seen in AR 1.0, VR 1.0 and CR0.2 for VCR
exposure only. The lowest SRs in the presence of 3.3 gM
VRP are obtained consistently for CR 2.0.
It can be seen that, in the presence of 6.6 gM VRP, SRs for
AR 1.0, VR 1.0 and CR 0.2 to ADM, VCR and COL are
increased compared to those obtained at the lower VRP dose
and generally exceed those obtained for the parent line.
Whereas an increase in the SRs for CR 2.0 is observed with
increased VRP dose, sensitisation of this line remains
generally less than that obtained for the parent line. Sensi-
tisation of all cell lines to VP 16 is only slightly increased at
the higher dose of VRP.
Chemosensitisation by cyclosporin A
Table IV shows that the parent line is sensitised to all four
drugs by 2.1 t4M CsA and that a clear increase in SR at the
higher dose of CsA is obtained for VCR and VP16 only. In
general, at 2.1 fLM CsA, SRs for MDR cell lines exceed
markedly those obtained for the parent line, although only
slight increases in SR are obtained for ADM at this dose. As
observed for low dose VRP, the lowest SRs obtained in the
MDR lines in the presence of low dose CsA are for CR 2.0.
Further increases in SR are obtained at 4.2 gLM CsA for all
cell lines to all drugs. No effects on cell growth were pro-
duced by CsA alone at 2.1 tLM but 20-30% growth inhibi-
tion was seen at 4.2 jLM in EMT6/P, CR0.2 and VR 1.0.
Dose-response curves
For EMT6/P, CR 0.2 and CR 2.0, detailed dose response
data were obtained for VRP and CsA in combination with
COL. Figure 5a shows a progressive increase in sensitisation
of the three lines with increasing VRP dose. However,
whereas only a small increase in SR is seen for the parent
Table III Effect of verapamil on the cytotoxic drug sensitivity of EMT6 sublines
Sensitisation ratio*
ADM VCR COL VP16
Cell VRP VRP VRP VRP
line 3.3 ym 6.6 iLM 3.3 ym 6.6ytM 3.3gm 6.6lM 3.3ym 6.6fLM
EMT6/P 4.3 8.2 1.1 2.2 2.6 3.0 1.6 1.8
7.5 8.6 1.7 4.0 1.6 2.0 2.1 2.1
3.8 8.0 1.8 3.5 2.0 2.8 1.6 2.1
6.6 1.7 5.6
AR 1.0 3.0 6.0 2.4 6.5 2.6 4.4 1.2 1.0
2.5 13.6 3.5 7.5 2.4 3.0 1.9 2.5
3.5
1.5
VR 1.0 5.4 10.8 4.7 15.0 2.0 3.7 1.1 2.5
4.1 15.3 3.2 7.2 2.3 3.7 1.4 2.3
CR 0.2 5.8 11.7 2.7 4.4 2.8 5.8 1.8 2.1
5.8 17.5 4.1 7.5 2.3 3.1 2.2 1.2
CR 2.0 0.8 6.5 1.7 5.9 2.2 8.0 0.9 1.5
0.8 2.3 1.4 3.5 1.0 1.8 1.1 1.0
1.4 4.0
aSensitisation ratio 1 1D50 in absence of modifier
ID50 in presence of modifier
Each value given represents the result of a separate experiment.CHEMOSENSITISATION BY VERAPAMIL AND CYCLOSPORIN A 93
Table IV Effect of cyclosporin A on the cytotoxic drug sensitivity of EMT6 sublines
Sensitisation ratioa
ADM VCR COL VP16
Cell CsA CsA CsA CsA
line 2.1 gm 4.2lM 2.1gM 4.2AM 2.1 JM 4.2 iM 2.1 Am 4.2gm
EMT6/P 19 21 2.8 5.0 4.6 5.5 3.6 5.9
22 16 4.8 8.3 5.1 6.0 3.8 6.3
14 18 3.3 5.0 7.5 8.6 3.5 5.3
8.2 10.4
AR 1.0 29 95 18 54 61 118 13 29
6.3 11 20 39 33 70 13 31
17 73 5.5 27 83
VR 1.0 43 60 17 30 50 143 23 51
23 50 54 88 47 70 23 78
37 100 52 75 58 106
CR 0.2 26 72 11 20 49 38 11 24
15 19 57 80 23 48 19 20
40 75 10 14 27 42
11 32 9.2 11 25 36
30 47 25
CR 2.0 24 72 6.0 25 12 180 7.8 30
7.0 11 7.9 30 20 65 10 20
35 72 15 104
24 44 18 50
aSee Table III.
Each value given represents the result of a separate experiment.
parent line than the CR 2.0 cell line. In contrast, sensitisation
of the CR 0.2 cell line is greater than that achieved in the
EMT6/P line throughout the CsA dose range investigated.
Although SRs for the CR 0.2 cell line increase steadily with
increasing CsA dose, the shape of the curve in Figure 5b
suggests that sensitisation may be approaching a plateau at
4.2JLM. In contrast, SRs for CR 2.0 rise sharply at 0.56jAM
and continue to do so throughout the CsA dose range.
CsA (PM)
Figure 5 Sensitisation ratios for cell lines EMT6/P (@), CR 0.2
(A) and CR 2.0 (U) exposed to colchicine and either VRP (a) or
CsA (b). Results shown are from a single experiment
- a repeat
experiment produced similar results.
line between 1.25 and 10 gLM VRP, a much greater increase in
SR is seen for the line CR 2.0 over this dose range.
Figure Sb shows dose-response data for CsA. It can be
seen that for the parent line there is a gradual increase in SR
with increasing CsA dose to 2.1 g.M. No further increase in
SR is seen at 4.2 tLM. As seen for low dose VRP, doses of
CsA between 0.26 and 1.0 gM give greater sensitisation of the
Discussion
The EMT6 MDR variants described in the present study
possess the biochemical and pharmacological characteristics
typical of the MDR phenotype: cross-resistance to struc-
turally and functionally unrelated cytotoxics, reduced cellular
drug accumulation, hyperexpression of P-glycoprotein and
partial reversal of drug resistance in the presence of the
calcium channel blocker VRP. Selected variants also hyper-
express the cytosolic calcium binding protein sorcin/CP22,
which is variably expressed in a number of MDR cell lines.
Consistent with previous findings (Bradley et al., 1988), the
degree ofdrug resistance shown by the EMT6 MDR variants
correlates well with the expression of P-glycoprotein only, in
that CR 2.0>AR 1.0>VR 1.0>CR 0.2>EMT6/P for both
P-glycoprotein and resistance. There is no apparent correla-
tion with CP22 expression. This observation is in accordance
with the concept that the gene for CP22 may be co-amplified
with the P-glycoprotein gene as part of a single amplicon but
is not a major determinant of drug resistance (van der Bliek
et al., 1986; Bradley et al., 1988). In the present study, these
MDR lines have been used to explore further the relationship
between chemosensitisation and the expression of P-
glycoprotein.
We have recently reported that MDR variants of the
EMT6 tumour cell line show collateral cross-resistance to
VRP, and that the degree of VRP resistance correlates with
the amount of membrane P-glycoprotein (Reeve et al., 1989).
These data indicate that VRP is itself a substrate for the
P-glycoprotein pump and are consistent with recent findings
which show that VRP and cytotoxic drugs bind competitively
to P-glycoprotein (Cornwell et al., 1987; Safa et al., 1987).
Importantly, determination of the apparent dissociation con-
stants for various agents revealed a range of cytotoxic drug
and sensitiser affinities for P-glycoprotein (Naito & Tsuruo,
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1989). Taken together, the aforementioned studies suggest
that the ability of a reversing agent to overcome drug resis-
tance to a particular cytotoxic in a given cell line is likely to
be determined by the affinity of the reversing agent and the
cytotoxic for P-glycoprotein and the amount of P-
glycoprotein.
Support for this contention is provided by the findings of
the present study. Comparison of the sensitisation efficacies
of VRP and CsA shows clearly that CsA is more effective in
overcoming MDR than VRP. Sensitisation of the MDR cell
lines is generally greater than that of the parent line even at
the lower dose of 2.1 tLM and is consistently greater than that
seen for VRP at 6.6,LM. Furthermore, in contrast to VRP,
considerable sensitisation to VP16 is achieved with CsA.
These findings are consistent with the observation that CsA
has a much higher affinity for P-glycoprotein than VRP
(Naito & Tsuruo, 1989) and thus support the contention that
the affinity of a reversing agent for P-glycoprotein is
indicative of its potency for overcoming drug resistance. Our
findings show that higher doses of VRP than of CsA are
generally required to produce SRs exceeding those seen in the
parent line. It is important to note, however, that sensitisa-
tion to VCR at 3.3 ,UM VRP is greater than that seen in the
parent for all MDR lines except CR 2.0. This observation is
consistent with the finding that resistance to vinca alkaloids
is more efficiently reversed by VRP than is resistance to
ADM (Tsuruo et al., 1983), an observation supported further
by the finding that, in contrast to the other cytotoxics
studied, a higher CsA dose is required in combination with
ADM to produce SRs in the MDR lines greater than those
seen in the parent line.
Our data also show that resistance to COL and VP16 is
less effectively reversed by VRP than resistance to VCR.
Both ADM and COL have lower affinities for P-glycoprotein
than VCR (Naito & Tsuruo, 1989) and hence might be less
effectively recognised and transported out of resistant cells by
P-glycoprotein. Other mechanisms of resistance might
therefore exist for these cytotoxic agents which result in a less
complete reversal of resistance by VRP. However, the data
show that CsA is able to overcome effectively resistance to
COL and VP16, possibly indicating that this sensitiser may
interact with multiple target molecules. Although both VRP
and CsA can partially or completely reverse the drug
accumulation defect seen in MDR cells (Nooter et al., 1989;
Coley et al., 1989b), it is of course also entirely possible that
these agents may each modify chemosensitivity by other
mechanisms in addition to their interaction with P-
glycoprotein.
The present study also shows the relationship between
sensitiser dose, SR and the amount of P-glycoprotein ex-
pressed by a given cell line to be extremely complex. In
general, the data shown in Tables III and IV do not indicate
a clear relationship between the SR and the P-glycoprotein
content for any of the cytotoxic drugs with either dose of
either sensitiser. However, the more complete dose-response
curves for EMT6/P, CR 0.2 and CR 2.0 exposed to COL in
the presence of different doses of VRP or CsA do indicate a
relationship between these parameters. In Figure 5a, it is only
at the highest dose of VRP (10 LM) that sensitisation of
CR 2.0 (high P-glycoprotein) exceeds that of EMT6/P and
CR 0.2 (low P-glycoprotein). This trend is more clearly seen
in Figure 5b, where sensitisation of CR 2.0 is actually less
than that of EMT6/P at low doses of CsA, but the trend is
reversed at higher doses. We believe that these data indicate
that the small degree of resistance seen in cell lines with low
P-glycoprotein can be optimally reversed by low sensitiser
doses whereas much higher sensitiser doses are required to
make a substantial impact on the high degrees of resistance
seen in lines with high P-glycoprotein. If this is true, then it
follows that the relative sensitisation measured in different
cell lines using only a single sensitiser dose, as reported in
many papers in the literature, is at best likely to be of limited
value and, at worst, positively misleading.
Hence the findings of the present study indicate chemosen-
sitisation to be a complex, multifactorial process depending
on the cytotoxic drug under study, the sensitiser employed,
sensitiser dose and the amount of P-glycoprotein in the target
cell line. While some normal tissues have been shown to
express high levels of P-glycoprotein, many normal cells con-
tain low or undetectable amounts (Fojo et al., 1987). A
potentially important clinical consequence of our observa-
tions is that low doses of a reversing agent may sensitise
relatively drug sensitive, low P-glycoprotein-containing, nor-
mal cells more effectively than drug-resistant tumour cells
which hyperexpress P-glycoprotein.
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